192 related articles for article (PubMed ID: 36843367)
1. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon?
Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B
Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367
[TBL] [Abstract][Full Text] [Related]
2. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
3. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.
Pereira BA; Vennin C; Papanicolaou M; Chambers CR; Herrmann D; Morton JP; Cox TR; Timpson P
Trends Cancer; 2019 Nov; 5(11):724-741. PubMed ID: 31735290
[TBL] [Abstract][Full Text] [Related]
4. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Lafaro KJ; Melstrom LG
Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
6. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
Huang HC; Sung YC; Li CP; Wan D; Chao PH; Tseng YT; Liao BW; Cheng HT; Hsu FF; Huang CC; Chen YT; Liao YH; Hsieh HT; Shih YC; Liu IJ; Wu HC; Lu TT; Wang J; Chen Y
Gut; 2022 Sep; 71(9):1843-1855. PubMed ID: 34921062
[TBL] [Abstract][Full Text] [Related]
7. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
9. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
11. Photodestruction of Stromal Fibroblasts Enhances Tumor Response to PDT in 3D Pancreatic Cancer Coculture Models.
Karimnia V; Rizvi I; Slack FJ; Celli JP
Photochem Photobiol; 2021 Mar; 97(2):416-426. PubMed ID: 33011973
[TBL] [Abstract][Full Text] [Related]
12. The pancreas cancer microenvironment.
Feig C; Gopinathan A; Neesse A; Chan DS; Cook N; Tuveson DA
Clin Cancer Res; 2012 Aug; 18(16):4266-76. PubMed ID: 22896693
[TBL] [Abstract][Full Text] [Related]
13. Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma.
Xiao H; Li X; Li B; Zhong Y; Qin J; Wang Y; Han S; Ren J; Shuai X
Acta Biomater; 2023 Apr; 161():265-274. PubMed ID: 36893956
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma.
Sperb N; Tsesmelis M; Wirth T
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752017
[TBL] [Abstract][Full Text] [Related]
15. Fibroblasts in pancreatic cancer: molecular and clinical perspectives.
Rebelo R; Xavier CPR; Giovannetti E; Vasconcelos MH
Trends Mol Med; 2023 Jun; 29(6):439-453. PubMed ID: 37100646
[TBL] [Abstract][Full Text] [Related]
16. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming.
Zhao T; Zhang R; He Q; Zhou H; Song X; Gong T; Zhang Z
Acta Biomater; 2022 Jun; 145():122-134. PubMed ID: 35381402
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.
Askan G; Sahin IH; Chou JF; Yavas A; Capanu M; Iacobuzio-Donahue CA; Basturk O; O'Reilly EM
BMC Cancer; 2021 Apr; 21(1):385. PubMed ID: 33836674
[TBL] [Abstract][Full Text] [Related]
19. Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids.
Saad MA; Zhung W; Stanley ME; Formica S; Grimaldo-Garcia S; Obaid G; Hasan T
Mol Pharm; 2022 Jul; 19(7):2549-2563. PubMed ID: 35583476
[TBL] [Abstract][Full Text] [Related]
20. Impacting Pancreatic Cancer Therapy in Heterotypic
Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
